Janagliflozin Treat Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 390 participants.
Also called NCT03851432
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 390 participants
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
- Registry
-
NCT03851432
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT03851432. Randomized; quadruple masking; primary purpose treatment. Start 2019-06-30 (actual); primary completion 2020-04-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Janagliflozin Treat Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Metformin
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Janagliflozin plus metformin
- Intervention (Drug)
- Janagliflozin plus metformin
- Intervention (Device)
- Placebo plus metformin
- Lead sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Record details
- Record id
cardio:ct-nct03851432- Content hash
597e4d932ebde22b52626fb20b0cf1ddd70f2ed94dc4937c0aff43015e0d9102